Clinical Trials Logo
  1. Home
  2. Uveitis, Posterior
  3. NCT03145025

Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant

Uveitis, Posterior Clinical Trial

Official title:
An Observational Change-From-Baseline Evaluation of Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant

Clinical Trial Summary

An Observational Change-From-Baseline Evaluation of Corneal Endothelial Cell Density in Eyes Treated with a Fluocinolone Acetonide Intravitreal Implant

Clinical Trial Description

This is a prospective, multicenter, open-label, single arm, observational evaluation of the corneal ECD change from baseline for subjects having the Retisert FA drug delivery system (0.59 mg) surgically implanted in the ocular vitreous chamber of at least 1 previously unimplanted eye for at least 1 year. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03145025
Study type Observational
Source Bausch & Lomb Incorporated
Contact
Status Completed
Phase
Start date July 14, 2017
Completion date March 22, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT00570479 - Prophylactic Anecortave Acetate in Patients With a Retisert Implant Phase 1
Recruiting NCT05486468 - The Use of Two YUTIQ Versus Sham for Treatment of Chronic Non Infectious Intraocular Inflammation Affecting the Posterior Segment Phase 3
Terminated NCT03656692 - Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer) Phase 4
Completed NCT02255032 - Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis Phase 2
Completed NCT00035906 - Research Study in Patients With Persistent Macular Edema Phase 2
Recruiting NCT05101928 - Ozurdex Monotherapy Trial Phase 4
Terminated NCT05070728 - Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI) Phase 3
Completed NCT02595398 - Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis Phase 3
Recruiting NCT03066869 - Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal Vasculitis Phase 4
Completed NCT01539577 - A Long-Term Safety Study of OZURDEX® in Clinical Practice N/A
Recruiting NCT05322070 - Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis Phase 4
Recruiting NCT06085079 - Ixekizumab for the Management of Refractory Non-Infectious Uveitis: A Proof-of-Concept Study Phase 4
Withdrawn NCT01905124 - Safety &Efficacy of CF101 to Subjects With Uveitis Phase 2
Completed NCT03598452 - High-dose Intravitreal Injection of Ganciclovir for the Treatment of CMVR in HIV-negative Patients N/A
Completed NCT02049476 - Study of the Effectiveness of Ozurdex for the Control of Uveitis Phase 4
Completed NCT00404612 - A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Phase 3
Completed NCT00404742 - A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Phase 3
Completed NCT02952001 - MAGNOLIA: Extension Study of Patients With Non-infectious Uveitis Who Participated in CLS1001-301
Not yet recruiting NCT06431373 - A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis Phase 3
Completed NCT03097315 - Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis Phase 3